Jonathan Levin to CD4 Lymphocyte Count
This is a "connection" page, showing publications Jonathan Levin has written about CD4 Lymphocyte Count.
Connection Strength
0,555
-
The impact of antiretroviral therapy on symptom burden among HIV outpatients with low CD4 count in rural Uganda: nested longitudinal cohort study. BMC Palliat Care. 2017 Jul 13; 17(1):8.
Score: 0,123
-
In utero and intra-partum HIV-1 transmission and acute HIV-1 infection during pregnancy: using the BED capture enzyme-immunoassay as a surrogate marker for acute infection. Int J Epidemiol. 2011 Aug; 40(4):945-54.
Score: 0,079
-
Effect of suicidality on clinical and behavioural outcomes in HIV positive adults in Uganda. PLoS One. 2021; 16(8):e0254830.
Score: 0,041
-
Effect of Stopping Cotrimoxazole Preventive Therapy on Microbial Translocation and Inflammatory Markers Among Human Immunodeficiency Virus-Infected Ugandan Adults on Antiretroviral Therapy: The COSTOP Trial Immunology Substudy. J Infect Dis. 2020 07 06; 222(3):381-390.
Score: 0,038
-
Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults. AIDS. 2017 02 20; 31(4):577-582.
Score: 0,030
-
Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study. Malar J. 2016 07 15; 15:361.
Score: 0,029
-
Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design. Contemp Clin Trials. 2015 Jul; 43:100-4.
Score: 0,026
-
Home-based versus clinic-based care for patients starting antiretroviral therapy with low CD4? cell counts: findings from a cluster-randomized trial. AIDS. 2014 Feb 20; 28(4):569-76.
Score: 0,024
-
Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis. 2011 Dec; 11(12):933-41.
Score: 0,021
-
Decreasing trends of bacteraemia among HIV-infected Ugandan adults: incidence, aetiology, clinical outcomes and effect of antiretroviral therapy in a semi-urban setting (2000-2008). Trop Med Int Health. 2011 Jun; 16(6):756-65.
Score: 0,020
-
Barriers to starting ART and how they can be overcome: individual and operational factors associated with early and late start of treatment. Trop Med Int Health. 2010 Nov; 15(11):1347-56.
Score: 0,019
-
Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):496-9.
Score: 0,018
-
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet. 2009 Dec 19; 374(9707):2080-2089.
Score: 0,018
-
Haematological and biochemistry laboratory abnormalities associated with splenomegaly in asymptomatic adults in Masaka, Uganda: implications for HIV biomedical prevention trials. Trop Med Int Health. 2010 Jan; 15(1):105-12.
Score: 0,018
-
Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009 Aug 11; 9:290.
Score: 0,018
-
Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res. 2008 Nov 20; 8:241.
Score: 0,017
-
Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr. 2008 Aug 01; 48(4):468-75.
Score: 0,016